CiMaas started in March 2015. The focus of CiMaas is the development of cellular immunotherapy for the treatment of cancer. The most advanced product is a dendritic cell (DC) vaccine. DC are able to activate the immune system and as such coordinate the activity of other immune cells that are able to attack the tumour cells. Currently CiMaas is busy to translate the research activities to clinical protocols and building it’s QM system in the new facility in Geleen. CiMaas expects to start a clinical trial with DC vaccines in later half of 2018.

Currently there are no vacancies. Please keep coming back to check for openings.